This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brenner, B. Articles by Kelsen, D. P. Search for Related Content PubMed PubMed Citation Articles by Brenner, B. Articles by Kelsen, D. P. Social Bookmarking                            What's this?

Small-Cell Carcinomas of the Gastrointestinal Tract: A Review

From the Gastrointestinal Oncology Service, the Department of Medicine, and the Department of Pathology, Memorial Sloan-Kettering Cancer Center; and the Weill School of Medicine, Cornell University, New York, NY

Address reprint requests to David P. Kelsen, MD, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021; e-mail: kelsend{at}mskcc.org

PURPOSE: To improve our understanding of the entity of small-cell carcinoma (SmCC) of the gastrointestinal (GI) tract.

METHODS: A MEDLINE search was done, using the terms "small cell carcinoma" or "oat cell carcinoma" combined with "gastrointestinal" or with any of the GI sites, for the period 1970 to 2003. The 138 eligible reports identified in this way were reviewed for clinical data.

RESULTS: To date, approximately 544 cases of GI SmCC have been reported. The disease represents 0.1% to 1% of all GI malignancies, with the esophagus being the most common primary site. A majority of patients present with overt distant metastases. Systemic symptoms are common; ectopic hormonal secretion may occur. By light microscopy, GI SmCCs are essentially indistinguishable from primary pulmonary SmCC. The presence of non-SmCC components is common. Data from molecular analysis of the disease has identified some similarities to pulmonary SmCC. Chemotherapy represents the main treatment option, with modest impact on survival. In locoregional disease, the literature suggests that treatment be initiated using chemoradiotherapy and then, if metastatic disease is still excluded, surgical resection be considered. The disease is highly aggressive, and survival is in the range of several weeks for untreated patients and of 6 to 12 months for those receiving therapy.

CONCLUSION: SmCC of the GI tract is a rare and lethal disease. Although there are many similarities to pulmonary SmCC, some differences between the two entities are suggested. While chemotherapy can achieve significant palliation, surgery may have a potential impact on long-term survival of patients with locoregional disease.

Supported in part by a grant from the Hester Diamond Fund.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. OCHSENREITHER, S. MARNITZ-SCHULTZE, A. SCHNEIDER, C. KOEHLER, S. DAUM, C. LODDENKEMPER, V. BUDACH, E. THIEL, U. KEILHOLZ, and A. SCHMITTEL Extrapulmonary Small Cell Carcinoma (EPSCC): 10 Years' Multi-disciplinary Experience at Charite Anticancer Res, August 1, 2009; 29(8): 3411 - 3415. [Abstract] [Full Text] [PDF]

				K. Chin, S. Baba, H. Hosaka, A. Ishiyama, N. Mizunuma, E. Shinozaki, M. Suenaga, T. Kozuka, Y. Seto, N. Yamamoto, et al. Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience Jpn. J. Clin. Oncol., June 2, 2008; (2008) hyn041v1. [Abstract] [Full Text] [PDF]

				G. Y. Ku, B. D. Minsky, V. W. Rusch, M. Bains, D. P. Kelsen, and D. H. Ilson Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience Ann. Onc., March 1, 2008; 19(3): 533 - 537. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, D. R. Spigel, S. Litchy, and F. A. Greco Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study J. Clin. Oncol., August 1, 2006; 24(22): 3548 - 3554. [Abstract] [Full Text] [PDF]

				T. Ishikubo, K. Akagi, M. Kurosumi, K. Yamaguchi, T. Fujimoto, H. Sakamoto, Y. Tanaka, and A. Ochiai Immunohistochemical and Mutational Analysis of c-kit in Gastrointestinal Neuroendocrine Cell Carcinoma Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 494 - 498. [Abstract] [Full Text] [PDF]

				P. Grabowski and H. Scherubl Expression of Neuroendocrine Markers in Undifferentiated Carcinomas of the Gastrointestinal Tract J. Clin. Oncol., July 20, 2005; 23(21): 4795 - 4795. [Full Text] [PDF]

				D. S. Klimstra, J. Shia, L. Tang, B. Brenner, and D. P. Kelsen In Reply: J. Clin. Oncol., July 20, 2005; 23(21): 4796 - 4797. [Full Text] [PDF]